Abstract
Implant-associated infection (IAI) remains a significant issue in orthopaedic surgery. Bacteriophages are naturally occurring viruses that kill bacteria. Bacteriophages are being considered as a reliable alternative and/or adjunct to antibiotics, especially with the rise of multidrug-resistant bacterial strains. The isolation of bacteriophages from the environment against major bacterial pathogens may be easier than searching for new antibiotics against these virulent bacterial stains. Although bacteriophages are not pathogenic to mammalian cells, they induce a humoral immune response in a mammalian host resulting in the formation of anti-phage antibodies that can influence the effect of phage therapy. We detail the experiences of several centers in Poland, the Republic of Georgia, the Russian Federation, and France that have extensive experience with phage therapy for IAI. Phage therapy is an emerging new paradigm for the treatment of IAI as multidrug-resistant bacteria become more common and national governments as well as global health agencies push to improve antibiotic stewardship in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ando H, Lemire S, Pires DP, Lu TK (2015) Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst 1:187–196. https://doi.org/10.1016/j.cels.2015.08.013
Baker SJ, Payne DJ, Rappuoli R, De Gregorio E (2018) Technologies to address antimicrobial resistance. Proc Natl Acad Sci U S A 115:12887–12895. https://doi.org/10.1073/pnas.1717160115
Barbarossa V, Matković BR, Vucić N, Bielen M, Gluhinić M (2001) Treatment of osteomyelitis and infected non-union of the femur by a modified Ilizarov technique: follow-up study. Croat Med J 42:634–641
Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:204–210. https://doi.org/10.1128/iai.70.1.204-210.2002
Burrowes BH, Molineux IJ, Fralick JA (2019) Directed in vitro evolution of therapeutic bacteriophages: the Appelmans protocol. Viruses 11:E241. https://doi.org/10.3390/v11030241
Cao F, Wang X, Wang L, Li Z, Che J, Wang L, Li X, Cao Z, Zhang J, Jin L, Xu Y (2015) Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int 2015:752930. https://doi.org/10.1155/2015/752930
Capparelli R, Nocerino N, Lanzetta R, Silipo A, Amoresano A, Giangrande C, Becker K, Blaiotta G, Evidente A, Cimmino A, Iannaccone M, Parlato M, Medaglia C, Roperto S, Roperto F, Ramunno L, Iannelli D (2010) Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. PLoS One 5:e11720. https://doi.org/10.1371/journal.pone.0011720
Center for Disease Dynamics, Economics and Policy (CDDEP) (2015) State of the world’s antibiotics, 2015. CDDEP, Washington, DC. https://cddep.org/publications/state_worlds_antibiotics_2015/
Centers for Disease Control and Prevention (CDC) (2013) Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 15 May 2019
Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783. https://doi.org/10.2217/fmb.13.47
Chanishvili N, Khurtsia N, Malkhazova I (2009) Phage therapy in surgery and wound treatment. In: Chanishvili N, Sharp R (eds) A literature review of the practical application of bacteriophage research. Eliava Institute, Tbilisi, pp 21–32
Chaudhry WN, Concepción-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 12:e0168615. https://doi.org/10.1371/journal.pone.0168615
Cheng M, Liang J, Zhang Y, Hu L, Gong P, Cai R, Zhang L, Zhang H, Ge J, Ji Y, Guo Z, Feng X, Sun C, Yang Y, Lei L, Han W, Gu J (2017) The bacteriophage ef-p29 efficiently protects against lethal vancomycin-resistant Enterococcus faecalis and alleviates gut microbiota imbalance in a murine bacteremia model. Front Microbiol 8:837. https://doi.org/10.3389/fmicb.2017.00837
Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH (2016) Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:239–251. https://doi.org/10.1016/S1473-3099(15)00466-1
D’Andrea MM, Marmo P, Henrici De Angelis L, Palmieri M, Ciacci N, Di Lallo G, Demattè E, Vannuccini E, Lupetti P, Rossolini GM, Thaller MC (2017) φBO1E, a newly discovered lytic bacteriophage targeting carbapenemase-producing Klebsiella pneumoniae of the pandemic Clonal Group 258 clade II lineage. Sci Rep 7:2614. https://doi.org/10.1038/s41598-017-02788-9
Dąbrowska K (2019) Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev 2019:1–26. https://doi.org/10.1002/med.21572
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730–733. https://doi.org/10.1038/s41591-019-0437-z
European Commission (2017) European one health action plan against antimicrobial resistance (AMR). https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf. Accessed 15 May 2019
Ferry T, Leboucher G, Fevre C, Herry Y, Conrad A, Josse J, Batailler C, Chidiac C, Medina M, Lustig S, Laurent F, Lyon BJI Study Group (2018) Salvage debridement, antibiotics and implant retention (“DAIR”) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing staphylococcus aureus prosthetic-joint infection? Open Forum Infect Dis 5:ofy269. https://doi.org/10.1093/ofid/ofy269
Gbejuade HO, Lovering AM, Webb JC (2015) The role of microbial biofilms in prosthetic joint infections. Acta Orthop 86:147–158. https://doi.org/10.3109/17453674.2014.966290
Gill JJ, Hyman P (2010) Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2–14. https://doi.org/10.2174/138920110790725311
Goren MG, Yosef I, Qimron U (2015) Programming bacteriophages by swapping their specificity determinants. Trends Microbiol 23:744–746. https://doi.org/10.1016/j.tim.2015.10.006
Górski A, Kniotek M, Perkowska-Ptasińska A, Mróz A, Przerwa A, Gorczyca W, Dąbrowska K, Weber-Dąbrowska B, Nowaczyk M (2006) Bacteriophages and transplantation tolerance. Transplant Proc 38:331–333. https://doi.org/10.1016/j.transproceed.2005.12.073
Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P, Jończyk-Matysiak E, Dąbrowska K, Majewska J, Borysowski J (2016) Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front Microbiol 7:1515. https://doi.org/10.3389/fmicb.2016.01515
Gosselin RA, Spiegel DA, Coughlin R, Zirkle LG (2009) Injuries: the neglected burden in developing countries. Bull World Health Organ 87:246–246a. https://doi.org/10.2471/BLT.08.052290
Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R, Sun C, Feng X (2012) A method for generation phage cocktail with great therapeutic potential. PLoS One 7:e31698. https://doi.org/10.1371/journal.pone.0031698
Heller KJ (1992) Molecular interaction between bacteriophage and the gram negative cell envelope. Arch Microbiol 158:235–248. https://doi.org/10.1007/bf00245239
Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP (2017) Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care 21:129. https://doi.org/10.1186/s13054-017-1709-y
Jończyk-Matysiak E, Łusiak-Szelachowska M, Kłak M, Bubak B, Międzybrodzki R, Weber-Dąbrowska B, Żaczek M, Fortuna W, Rogóż P, Letkiewicz S, Szufnarowski K, Górski A (2015) The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J Immunol Res 2015:482863. https://doi.org/10.1155/2015/482863
Kamal F, Dennis JJ (2015) Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity. Appl Environ Microbiol 81:1132–1138. https://doi.org/10.1128/AEM.02850-14
Kaur S, Harjai K, Chhibber S (2014) Bacteriophage mediated killing of Staphylococcus aureus in vitro on orthopaedic K wires in presence of linezolid prevents implant colonization. PLoS One 9:e90411. https://doi.org/10.1371/journal.pone.0090411
Keen EC (2015) A century of phage research: bacteriophages and the shaping of modern biology. BioEssays 37:6–9. https://doi.org/10.1002/bies.201400152
Kortram K, Bezstarosti H, Metsemakers WJ, Raschke MJ, Van Lieshout EMM, Verhofstad MHJ (2017) Risk factors for infectious complications after open fractures; a systematic review and meta-analysis. Int Orthop 41:1965–1982. https://doi.org/10.1007/s00264-017-3556-5
Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J (2012) Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 27(8):61–65. https://doi.org/10.1016/j.arth.2012.02.022
Kurzępa-Skaradzińska A, Łusiak-Szelachowska M, Skaradziński G, Jończyk-Matysiak E, Weber-Dąbrowska B, Żaczek M, Maj T, Sławek A, Rymowicz W, Kłak M, Międzybrodzki R, Górski A (2013) Influence of bacteriophage preparations on intracellular killing of bacteria by human phagocytes in vitro. Viral Immunol 26:150–162. https://doi.org/10.1089/vim.2012.0071
Labrie S, Samson J, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327. https://doi.org/10.1038/nrmicro2315
Lehman SM, Mearns G, Rankin D, Cole RA, Smrekar F, Branston SD, Morales S (2019) Design and preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus infections. Viruses 11:E88. https://doi.org/10.3390/v11010088
León M, Bastías R (2015) Virulence reduction in bacteriophage resistant bacteria. Front Microbiol 6:343. https://doi.org/10.3389/fmicb.2015.00343
Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2:166–173. https://doi.org/10.1038/nrmicro822
Li B, Webster TJ (2018) Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J Orthop Res 36:22–32. https://doi.org/10.1002/jor.23656
Lindberg AA (1973) Bacteriophage receptors. Annu Rev Microbiol 27:205–241. https://doi.org/10.1146/annurev.mi.27.100173.001225
Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B, Międzybrodzki R, Kłak M, Fortuna W, Letkiewicz S, Rogóż P, Szufnarowski K, Jończyk-Matysiak E, Owczarek B, Górski A (2014) Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27:295–304. https://doi.org/10.1089/vim.2013.0128
Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Letkiewicz S, Fortuna W, Rogóż P, Szufnarowski K, Jończyk-Matysiak E, Olchawa E, Walaszek KM, Górski A (2017) Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbiol 12:109–117. https://doi.org/10.2217/fmb-2016-0156
Mapes AC, Trautner BW, Liao KS, Ramig RF (2016) Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage 6:e1096995. https://doi.org/10.1080/21597081.2015.1096995
Matusis EE, Shumilkina EI, Boiarinova LV (1974) Use of therapeutic bacteriophages in complex treatment of faked joints of shin bones aggravated with osteomyelitis. In: Selected articles of the jubilee symposium dedicated to the 50th anniversary of the Tbilisi Institute of Vaccine and Sera. TIVS, Tbilisi, pp 367–369
Matsunaga N, Hayakawa K (2018) Estimating the impact of antimicrobial resistance. Lancet Glob Health 6:e934–e935. https://doi.org/10.1016/S2214-109X(18)30325-5
Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187:613–624. https://doi.org/10.1086/374001
McNally M, Ferguson J, Kugan R, Stubbs D (2017) Ilizarov treatment protocols in the management of infected nonunion of the tibia. J Orthop Trauma 31(5):S47–S54. https://doi.org/10.1097/BOT.0000000000000987
Międzybrodzki R, Świtała-Jeleń K, Fortuna W, Weber-Dąbrowska B, Przerwa A, Kurzępa A, Łusiak-Szelachowska M, Dąbrowska K, Boratyński J, Syper D, Ługowski C, Poźniak G, Górski A (2008) Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res 131:233–242. https://doi.org/10.1016/j.virusres.2007.09.013
Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłak M, Wojtasik E, Górski A (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73–121. https://doi.org/1016/B978-0-12-394438-2.00003-7
Międzybrodzki R, Borysowski J, Kłak M, Jończyk-Matysiak E, Obmińska-Mrukowicz B, Suszko-Pawłowska A, Bubak B, Weber-Dąbrowska B, Górski A (2017a) In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. Biomed Res Int 2017:3612015. https://doi.org/10.1155/2017/3612015
Międzybrodzki R, Kłak M, Jończyk-Matysiak E, Bubak B, Wójcik A, Kaszowska M, Weber-Dąbrowska B, Łobocka M, Górski A (2017b) Means to facilitate the overcoming of gastric juice barrier by a therapeutic staphylococcal bacteriophage A5/80. Front Microbiol 8:467. https://doi.org/10.3389/fmicb.2017.00467
Międzybrodzki R, Hoyle N, Zhvaniya F, Łusiak-Szelachowska M, Weber-Dąbrowska B, Łobocka M, Borysowski J, Alavidze Z, Kutter E, Górski A, Gogokhia L (2018) Current updates from the long-standing phage research centers in Georgia, Poland, and Russia. In: Harper D, Abedon S, Burrowes B, McConville M (eds) Bacteriophages. Springer, Cham, pp 1–31. https://doi.org/10.1007/978-3-319-40598-8
Miernikiewicz P, Kłopot A, Soluch R, Szkuta P, Kęska W, Hodyra-Stefaniak K, Konopka A, Nowak M, Lecion D, Kaźmierczak Z, Majewska J, Harhala M, Górski A, Dąbrowska K (2016) T4 phage tail adhesin gp12 counteracts LPS-induced inflammation in vivo. Front Microbiol 7:1112. https://doi.org/10.3389/fmicb.2016.01112
Morgenstern M, Post V, Erichsen C, Hungerer S, Bühren V, Militz M, Richards RG, Moriarty TF (2016) Biofilm formation increases treatment failure in Staphylococcus epidermidis device-related osteomyelitis of the lower extremity in human patients. J Orthop Res 34:1905–1913. https://doi.org/10.1002/jor.23218
Morris J, Kelly N, Elliott L, Grant A, Wilkinson M, Hazratwala K, McEwen P (2019) Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus. Surg Infect 20:16–24. https://doi.org/10.1089/sur.2018.135
Nesper J, Kapfhammer D, Klose KE, Merkert H, Reidl J (2000) Characterization of Vibrio cholerae O1 antigen as the bacteriophage K139 receptor and identification of IS1004 insertions aborting O1 antigen biosynthesis. J Bacteriol 182:5097–5104. https://doi.org/10.1128/jb.182.18.5097-5104.2000
Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, Khalifa L, Rimon A, Yerushalmy O, Bader R, Amit S, Coppenhagen-Glazer S, Henry M, Quinones J, Malagon F, Biswas B, Moses AE, Merril G, Schooley RT, Brownstein MJ, Weil YA, Hazan R (2019) Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis:ciz222. https://doi.org/10.1093/cid/ciz222
O’Neill J (ed.) (2016) Tackling drug-resistant infections globally: final report and recommendations. Available via Review on Antimicrobial Resistance. http://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed 15 May 2019
Oechslin F (2018) Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses 10:351. https://doi.org/10.3390/v10070351
Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA (2017) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis 215:703–712. https://doi.org/10.1093/infdis/jiw632
Ormälä AM, Jalasvuori M (2013) Phage therapy: should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 3:e24219. https://doi.org/10.4161/bact.24219
Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A (2018) Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. Viruses 11:pii: E18. https://doi.org/10.3390/v11010018
Pherecydes Pharma (2019a) PHOSA: a collaborative research project for the development of an innovative phage therapy treatment against bone/joint and diabetic foot ulcer infections. https://www.pherecydes-pharma.com/phosa-collaborative-project.html. Accessed 15 May 2019
Pherecydes Pharma (2019b) PHOSAClin: clinical study of application of phagotherapy to treat Staphylococcus aureus infections of the diabetic foot ulcer. https://www.pherecydes-pharma.com/clinical-study-phosaclin.html. Accessed 15 May 2019
Pires DP, Oliveira H, Melo LD, Sillankorva S, Azeredo J (2016) Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 100:2141–2151. https://doi.org/10.1007/s00253-015-7247-0
Pires DP, Melo L, Vilas Boas D, Sillankorva S, Azeredo J (2017) Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol 39:48–56. https://doi.org/10.1016/j.mib.2017.09.004
Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, Fauconnier A (2018) The magistral phage. Viruses 10:E64. https://doi.org/10.3390/v10020064
Plakseychuk A, Plakseychuk Y, Gruen GS, Ziran BH (2002) Treatment of osteomyelitis with Ilizarov frame. Oper Tech Orthop 12:273–281. https://doi.org/10.1053/otor.2002.36312
Rios AC, Moutinho CG, Pinto FC, Del Fiol FS, Jozala A, Chaud MV, Vila MM, Teixeira JA, Balcão VM (2016) Alternatives to overcoming bacterial resistances: state-of-the-art. Microbiol Res 191:51–80. https://doi.org/10.1016/j.micres.2016.04.008
Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L (2017) Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22:38–47. https://doi.org/10.1016/j.chom.2017.06.018
Samokhin AG, Fedorov EA, Kozlova YN, Tikunova NV, Pavlov VV, Morozova VV, Kretien SO (2016) Application of the lytic bacteriophages during surgical treatment of the periprosthetic infection of the hip joint endoprosthesis (pilot study). Sovremennye problemy nauki i obrazovaniya. 2016:(6). (in Russian). https://doi.org/10.17513/spno.25851
Samokhin AG, Kozlova YN, Korneev DV, Taranov OS, Fedorov EA, Pavlov VV, Morozova VV, Tikunova NV (2018) Experimental study of the antibacterial activity of the lytic Staphylococcus aureus bacteriophage ph20 and lytic Pseudomonas aeruginosa bacteriophage ph57 during modelling of its impregnation into poly(methylmetacrylate) orthopedic implants (bone cement). Ann Rus Acad Med Sci 73:59–68. (in Russian). https://doi.org/10.15690/vramn905
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954-17. https://doi.org/10.1128/AAC.00954-17
Ślopek S, Weber-Dąbrowska B, Dąbrowski M, Kucharewicz-Krukowska A (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp 35:569–583
Smith HW, Huggins MB (1983) Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129:2659–2675. https://doi.org/10.1099/00221287-129-8-2659
Stewart KA, Groen RS, Kamara TB, Farahzad MM, Samai M, Cassidy LD, Kushner AL, Wren SM (2013) Traumatic injuries in developing countries: report from a nationwide cross-sectional survey of Sierra Leone. JAMA Surg 148:463–469. https://doi.org/10.1001/jamasurg.2013.1341
Torres-Barceló C, Franzon B, Vasse M, Hochberg ME (2016) Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa. Evol Appl 9:583–595. https://doi.org/10.1111/eva.12364
Ulrich SD, Seyler TM, Bennett D, Delanois RE, Saleh KJ, Thongtrangan I, Kuskowski M, Cheng EY, Sharkey PF, Parvizi J, Stiehl JB, Mont MA (2008) Total hip arthroplasties: what are the reasons for revision? Int Orthop 32:597–604. https://doi.org/10.1007/s00264-007-0364-3
Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M (2017) Pro-and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep 7:8004. https://doi.org/10.1038/s41598-017-08336-9
Wang J, Hu B, Xu M, Yan O, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J (2006a) Use of bacteriophage in the treatment of experimental bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17:309–317. https://doi.org/10.3892/ijmm.17.2.309
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ, Hu J (2006b) Therapeutic effectiveness of bacteriophages in the rescue of mice with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 17:347–355. https://doi.org/10.3892/ijmm.17.2.347
Weber-Dąbrowska B, Jończyk-Matysiak E, Żaczek M, Łobocka M, Łusiak-Szelachowska M, Górski A (2016) Bacteriophage procurement for therapeutic purposes. Front Microbiol 7:1177. https://doi.org/10.3389/fmicb.2016.01177
World Health Organization (2015) Global action plan on antimicrobial resistance. http://www.who.int/iris/handle/10665/193736. Accessed 15 May 2019
World Health Organization (2018) Global status report on road safety 2018. World Health Organization, Geneva, (WHO/NMH/NVI/18.20). https://www.who.int/violence_injury_prevention/road_safety_status/2018/en/. Accessed 15 May 2019
Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M (2013) Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am 95:117–125. https://doi.org/10.2106/JBJS.K.01135
Żaczek M, Łusiak-Szelachowska M, Jończyk-Matysiak E, Weber-Dąbrowska B, Międzybrodzki R, Owczarek B, Kopciuch A, Fortuna W, Rogóż P, Górski A (2016) Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front Microbiol 7:1681. https://doi.org/10.3389/fmicb.2016.01681
Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J (2013) Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am 95:2177–2184. https://doi.org/10.2106/JBJS.L.00789
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rogóż, P. et al. (2019). Phage Therapy in Orthopaedic Implant-Associated Infections. In: Górski, A., Międzybrodzki, R., Borysowski, J. (eds) Phage Therapy: A Practical Approach. Springer, Cham. https://doi.org/10.1007/978-3-030-26736-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-26736-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-26735-3
Online ISBN: 978-3-030-26736-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)